ProQR Therapeutics (NASDAQ:PRQR) Posts Earnings Results, Hits Estimates

ProQR Therapeutics (NASDAQ:PRQR) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting analysts’ consensus estimates of ($0.15), FiscalAI reports. The firm had revenue of $2.35 million during the quarter, compared to analysts’ expectations of $5.19 million. ProQR Therapeutics had a negative net margin of 255.83% and a negative return on equity of 65.89%.

ProQR Therapeutics Stock Down 0.9%

NASDAQ:PRQR traded down $0.02 during trading hours on Thursday, hitting $1.69. 244,345 shares of the company traded hands, compared to its average volume of 522,582. The firm’s 50-day simple moving average is $1.69 and its 200-day simple moving average is $1.87. ProQR Therapeutics has a one year low of $1.33 and a one year high of $3.10. The company has a market cap of $177.53 million, a PE ratio of -3.66 and a beta of 0.08.

Analysts Set New Price Targets

A number of research analysts recently issued reports on PRQR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a report on Tuesday, April 21st. Oppenheimer started coverage on shares of ProQR Therapeutics in a report on Thursday, March 12th. They issued an “outperform” rating and a $9.00 price objective for the company. Chardan Capital reiterated a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a report on Thursday, April 9th. Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a report on Friday, March 13th. Finally, Wall Street Zen upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, March 14th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of PRQR. Osaic Holdings Inc. grew its holdings in shares of ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares in the last quarter. Guggenheim Capital LLC purchased a new position in shares of ProQR Therapeutics during the fourth quarter worth about $35,000. Invesco Ltd. purchased a new position in shares of ProQR Therapeutics during the fourth quarter worth about $51,000. Simplex Trading LLC grew its holdings in shares of ProQR Therapeutics by 44,169.0% during the fourth quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company’s stock worth $89,000 after purchasing an additional 44,169 shares in the last quarter. Finally, Persistent Asset Partners Ltd grew its holdings in shares of ProQR Therapeutics by 24.5% during the fourth quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock worth $91,000 after purchasing an additional 8,874 shares in the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.